Does empagliflozin reduce cardiac inflammation and blunt worsening cardiac dysfunction in heart failure?
Empagliflozin blunts worsening cardiac dysfunction by reducing NLRP3 inflammasome activation, suggesting a mechanism for its benefit in heart failure independent of diabetes.
These data provide evidence that the beneficial cardiac effects of empagliflozin are associated with reduced cardiac inflammation via blunting activation of the NLRP3 inflammasome in a Ca2+-dependent manner and hence may be beneficial in treating HF even in the absence of diabetes mellitus.
Byrne et al. (Wed,) studied this question.